KR20160060656A - 폴리에틸렌글리콜 함유 조성물 - Google Patents

폴리에틸렌글리콜 함유 조성물 Download PDF

Info

Publication number
KR20160060656A
KR20160060656A KR1020167008149A KR20167008149A KR20160060656A KR 20160060656 A KR20160060656 A KR 20160060656A KR 1020167008149 A KR1020167008149 A KR 1020167008149A KR 20167008149 A KR20167008149 A KR 20167008149A KR 20160060656 A KR20160060656 A KR 20160060656A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
formula
polyethylene glycol
compound
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020167008149A
Other languages
English (en)
Korean (ko)
Inventor
켄지 무라이
가즈히토 야마다
Original Assignee
산텐 세이야꾸 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 산텐 세이야꾸 가부시키가이샤 filed Critical 산텐 세이야꾸 가부시키가이샤
Publication of KR20160060656A publication Critical patent/KR20160060656A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
KR1020167008149A 2013-09-20 2014-09-18 폴리에틸렌글리콜 함유 조성물 Withdrawn KR20160060656A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2013-195329 2013-09-20
JP2013195329 2013-09-20
PCT/JP2014/074698 WO2015041294A1 (ja) 2013-09-20 2014-09-18 ポリエチレングリコール含有組成物

Publications (1)

Publication Number Publication Date
KR20160060656A true KR20160060656A (ko) 2016-05-30

Family

ID=52688941

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167008149A Withdrawn KR20160060656A (ko) 2013-09-20 2014-09-18 폴리에틸렌글리콜 함유 조성물

Country Status (17)

Country Link
US (1) US20160228420A1 (enExample)
EP (1) EP3047850A4 (enExample)
JP (2) JP5856264B2 (enExample)
KR (1) KR20160060656A (enExample)
CN (1) CN105555271A (enExample)
AU (1) AU2014322111A1 (enExample)
BR (1) BR112016006153A2 (enExample)
CA (1) CA2924628A1 (enExample)
EA (1) EA201690621A1 (enExample)
HK (2) HK1220632A1 (enExample)
IL (1) IL244648A0 (enExample)
MX (1) MX2016003566A (enExample)
MY (1) MY163236A (enExample)
PH (1) PH12016500461A1 (enExample)
SG (1) SG11201602020QA (enExample)
TW (1) TW201518291A (enExample)
WO (1) WO2015041294A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102538806B1 (ko) * 2015-03-17 2023-05-31 산텐 세이야꾸 가부시키가이샤 폴리펩티드를 함유하는 의약 조성물
WO2016148228A1 (ja) 2015-03-18 2016-09-22 参天製薬株式会社 徐放性医薬組成物
JP2017008047A (ja) * 2015-06-25 2017-01-12 参天製薬株式会社 注射剤
AR105215A1 (es) * 2015-07-01 2017-09-13 Santen Pharmaceutical Co Ltd Formulación de depósito que contiene ésteres de ácido cítrico
CN106902117A (zh) * 2015-12-23 2017-06-30 瑞阳(苏州)生物科技有限公司 一种预防或治疗脉络膜新生血管形成的药物
JP7018939B2 (ja) * 2016-09-26 2022-02-14 ルヤン （スーチョウ） バイオロジー サイエンス アンド テクノロジー カンパニー，リミテッド 眼疾患の治療のための組成物ならびに使用および調製方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA833692B (en) * 1982-05-28 1985-02-27 Beecham Group Plc Pharmaceutical formulations
JPS59101478A (ja) * 1982-11-29 1984-06-12 Sunstar Inc リグスチライドを安定に配合した水系組成物
JPH09110698A (ja) * 1995-10-19 1997-04-28 Taiho Yakuhin Kogyo Kk 経口用医薬組成物の製造法
CN1918127B (zh) * 2004-02-17 2012-02-15 参天制药株式会社 具有引入了取代或无取代氨基的4-吡啶基烷硫基的环状化合物
US7544703B2 (en) 2004-02-17 2009-06-09 Santen Pharmaceutical Co., Ltd. Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein
JP4626353B2 (ja) * 2004-02-17 2011-02-09 参天製薬株式会社 置換又は無置換アミノ基を導入した４−ピリジルアルキルチオ基を有する新規環式化合物
US20060153920A1 (en) * 2004-09-24 2006-07-13 Ketan Amin Lyophilized pharmaceutical compositions
EP1853259A1 (en) * 2005-02-09 2007-11-14 Macusight, Inc. Formulations for ocular treatment
JP2009521493A (ja) 2005-12-23 2009-06-04 アルコン，インコーポレイテッド 眼への受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の送達のための医薬製剤
AU2007356856A1 (en) 2007-07-20 2009-01-29 Alcon, Inc. Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (RTKI) compounds to the eye
WO2009070687A1 (en) * 2007-11-26 2009-06-04 Merial Limited Solvent systems for pour-on formulations for combating parasites
WO2010101971A1 (en) 2009-03-03 2010-09-10 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
MY157122A (en) 2009-07-17 2016-05-13 Santen Pharmaceutical Co Ltd 2 - [[[2 -[(hydroxyacetyl) amino]- 4 -pyridinyl] methyl]thio]- n -[4 - (trifluoromethoxy) phenyl]- 3 -pyridinecarboxamide benzene-sulfonate, crystal of same, polymorph thereof, and processes for production thereof
EP3895694A1 (en) * 2010-01-28 2021-10-20 Eagle Pharmaceuticals, Inc. Formulations of bendamustine

Also Published As

Publication number Publication date
HK1221407A1 (en) 2017-06-02
EP3047850A4 (en) 2017-05-10
SG11201602020QA (en) 2016-04-28
AU2014322111A1 (en) 2016-04-07
CA2924628A1 (en) 2015-03-26
CN105555271A (zh) 2016-05-04
IL244648A0 (en) 2016-04-21
EP3047850A1 (en) 2016-07-27
JP2016094442A (ja) 2016-05-26
MX2016003566A (es) 2016-06-02
MY163236A (en) 2017-08-30
WO2015041294A1 (ja) 2015-03-26
US20160228420A1 (en) 2016-08-11
PH12016500461A1 (en) 2016-05-16
EA201690621A1 (ru) 2016-07-29
HK1220632A1 (zh) 2017-05-12
JP2015083565A (ja) 2015-04-30
TW201518291A (zh) 2015-05-16
JP5856264B2 (ja) 2016-02-09
BR112016006153A2 (pt) 2017-08-01

Similar Documents

Publication Publication Date Title
JP7726542B2 (ja) ピリジルアミノ酢酸化合物を含む医薬製剤
CN107708738B (zh) 含有柠檬酸酯的贮库制剂
KR20160060656A (ko) 폴리에틸렌글리콜 함유 조성물
KR20170129170A (ko) 서방성 의약 조성물
JP2021095406A (ja) ピリジルアミノ酢酸化合物を含有する予防及び／又は治療剤
TWI677346B (zh) 含有多肽之醫藥組成物
HK1243347B (en) Pharmaceutical composition comprising polypeptide
WO2016148227A1 (ja) 医薬組成物の安定保存
HK1246167A1 (en) Depot preparation containing citric acid ester
HK1255586B (en) Pharmaceutical composition comprising polypeptide

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160328

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid